- Home
- SOLV vs SMMT Comparison
SOLV vs SMMT Comparison
Compare SOLV & SMMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOLV
- SMMT
- Stock Information
- Founded
- SOLV 2023
- SMMT 2003
- Country
- SOLV United States
- SMMT United States
- Employees
- SOLV N/A
- SMMT N/A
- Industry
- SOLV
- SMMT Biotechnology: Pharmaceutical Preparations
- Sector
- SOLV
- SMMT Health Care
- Exchange
- SOLV NYSE
- SMMT Nasdaq
- Market Cap
- SOLV 12.6B
- SMMT 14.5B
- IPO Year
- SOLV N/A
- SMMT N/A
- Fundamental
- Price
- SOLV $67.52
- SMMT $18.31
- Analyst Decision
- SOLV Hold
- SMMT Strong Buy
- Analyst Count
- SOLV 9
- SMMT 4
- Target Price
- SOLV $68.00
- SMMT $34.75
- AVG Volume (30 Days)
- SOLV 1.1M
- SMMT 2.1M
- Earning Date
- SOLV 11-26-2024
- SMMT 10-30-2024
- Dividend Yield
- SOLV N/A
- SMMT N/A
- EPS Growth
- SOLV N/A
- SMMT N/A
- EPS
- SOLV 4.16
- SMMT N/A
- Revenue
- SOLV $8,215,000,000.00
- SMMT N/A
- Revenue This Year
- SOLV $2.17
- SMMT N/A
- Revenue Next Year
- SOLV $0.30
- SMMT N/A
- P/E Ratio
- SOLV $16.21
- SMMT N/A
- Revenue Growth
- SOLV 0.60
- SMMT N/A
- 52 Week Low
- SOLV $47.16
- SMMT $1.88
- 52 Week High
- SOLV $77.17
- SMMT $33.89
- Technical
- Relative Strength Index (RSI)
- SOLV N/A
- SMMT 41.16
- Support Level
- SOLV N/A
- SMMT $19.01
- Resistance Level
- SOLV N/A
- SMMT $22.53
- Average True Range (ATR)
- SOLV 0.00
- SMMT 1.45
- MACD
- SOLV 0.00
- SMMT -0.21
- Stochastic Oscillator
- SOLV 0.00
- SMMT 4.85
About SOLV SOLVENTUM CORP
Solventum Corp is an independent healthcare company with a primary focus on addressing healthcare challenges. Its diverse product portfolio spans the healthcare industry, including medical solutions, oral care, health information systems, and separation and purification sciences.
About SMMT Summit Therapeutics Inc.
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.